These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
24. Genetically engineered mouse models shed new light on the pathogenesis of neurofibromatosis type I-related neoplasms of the peripheral nervous system. Brossier NM; Carroll SL Brain Res Bull; 2012 May; 88(1):58-71. PubMed ID: 21855613 [TBL] [Abstract][Full Text] [Related]
25. Prognostic significance of AKT/mTOR and MAPK pathways and antitumor effect of mTOR inhibitor in NF1-related and sporadic malignant peripheral nerve sheath tumors. Endo M; Yamamoto H; Setsu N; Kohashi K; Takahashi Y; Ishii T; Iida K; Matsumoto Y; Hakozaki M; Aoki M; Iwasaki H; Dobashi Y; Nishiyama K; Iwamoto Y; Oda Y Clin Cancer Res; 2013 Jan; 19(2):450-61. PubMed ID: 23209032 [TBL] [Abstract][Full Text] [Related]
26. Detection of malignant peripheral nerve sheath tumors in patients with neurofibromatosis using aneuploidy and mutation identification in plasma. Mattox AK; Douville C; Silliman N; Ptak J; Dobbyn L; Schaefer J; Popoli M; Blair C; Judge K; Pollard K; Pratilas C; Blakeley J; Rodriguez F; Papadopoulos N; Belzberg A; Bettegowda C Elife; 2022 Mar; 11():. PubMed ID: 35244537 [TBL] [Abstract][Full Text] [Related]
27. RAS/MEK-independent gene expression reveals BMP2-related malignant phenotypes in the Nf1-deficient MPNST. Sun D; Haddad R; Kraniak JM; Horne SD; Tainsky MA Mol Cancer Res; 2013 Jun; 11(6):616-27. PubMed ID: 23423222 [TBL] [Abstract][Full Text] [Related]
28. MicroRNA-10b regulates tumorigenesis in neurofibromatosis type 1. Chai G; Liu N; Ma J; Li H; Oblinger JL; Prahalad AK; Gong M; Chang LS; Wallace M; Muir D; Guha A; Phipps RJ; Hock JM; Yu X Cancer Sci; 2010 Sep; 101(9):1997-2004. PubMed ID: 20550523 [TBL] [Abstract][Full Text] [Related]
29. Association between benign and malignant peripheral nerve sheath tumors in NF1. Tucker T; Wolkenstein P; Revuz J; Zeller J; Friedman JM Neurology; 2005 Jul; 65(2):205-11. PubMed ID: 16043787 [TBL] [Abstract][Full Text] [Related]
31. Translationally controlled tumor protein is a novel biological target for neurofibromatosis type 1-associated tumors. Kobayashi D; Hirayama M; Komohara Y; Mizuguchi S; Wilson Morifuji M; Ihn H; Takeya M; Kuramochi A; Araki N J Biol Chem; 2014 Sep; 289(38):26314-26326. PubMed ID: 25092287 [TBL] [Abstract][Full Text] [Related]
32. The activation of the WNT signaling pathway is a Hallmark in neurofibromatosis type 1 tumorigenesis. Luscan A; Shackleford G; Masliah-Planchon J; Laurendeau I; Ortonne N; Varin J; Lallemand F; Leroy K; Dumaine V; Hivelin M; Borderie D; De Raedt T; Valeyrie-Allanore L; Larousserie F; Terris B; Lantieri L; Vidaud M; Vidaud D; Wolkenstein P; Parfait B; Bièche I; Massaad C; Pasmant E Clin Cancer Res; 2014 Jan; 20(2):358-71. PubMed ID: 24218515 [TBL] [Abstract][Full Text] [Related]
33. Microarray-based copy number analysis of neurofibromatosis type-1 (NF1)-associated malignant peripheral nerve sheath tumors reveals a role for Rho-GTPase pathway genes in NF1 tumorigenesis. Upadhyaya M; Spurlock G; Thomas L; Thomas NS; Richards M; Mautner VF; Cooper DN; Guha A; Yan J Hum Mutat; 2012 Apr; 33(4):763-76. PubMed ID: 22331697 [TBL] [Abstract][Full Text] [Related]
34. The Ras inhibitor farnesylthiosalicylic acid as a potential therapy for neurofibromatosis type 1. Barkan B; Starinsky S; Friedman E; Stein R; Kloog Y Clin Cancer Res; 2006 Sep; 12(18):5533-42. PubMed ID: 17000690 [TBL] [Abstract][Full Text] [Related]
35. Gene expression analysis identifies potential biomarkers of neurofibromatosis type 1 including adrenomedullin. Hummel TR; Jessen WJ; Miller SJ; Kluwe L; Mautner VF; Wallace MR; Lázaro C; Page GP; Worley PF; Aronow BJ; Schorry EK; Ratner N Clin Cancer Res; 2010 Oct; 16(20):5048-57. PubMed ID: 20739432 [TBL] [Abstract][Full Text] [Related]
36. Methylation analysis of the neurofibromatosis type 1 (NF1) promoter in peripheral nerve sheath tumours. Harder A; Rosche M; Reuss DE; Holtkamp N; Uhlmann K; Friedrich R; Mautner VF; von Deimling A Eur J Cancer; 2004 Dec; 40(18):2820-8. PubMed ID: 15571966 [TBL] [Abstract][Full Text] [Related]
37. MEK inhibition exhibits efficacy in human and mouse neurofibromatosis tumors. Jessen WJ; Miller SJ; Jousma E; Wu J; Rizvi TA; Brundage ME; Eaves D; Widemann B; Kim MO; Dombi E; Sabo J; Hardiman Dudley A; Niwa-Kawakita M; Page GP; Giovannini M; Aronow BJ; Cripe TP; Ratner N J Clin Invest; 2013 Jan; 123(1):340-7. PubMed ID: 23221341 [TBL] [Abstract][Full Text] [Related]
38. Peripheral nerve sheath tumors from patients with neurofibromatosis type 1 do not have the chromosomal translocation t(X;18). Liew MA; Coffin CM; Fletcher JA; Hang MT; Tanito K; Niimura M; Viskochil D Pediatr Dev Pathol; 2002; 5(2):165-9. PubMed ID: 11910511 [TBL] [Abstract][Full Text] [Related]
39. Atypical neurofibromas in neurofibromatosis type 1 are premalignant tumors. Beert E; Brems H; Daniëls B; De Wever I; Van Calenbergh F; Schoenaers J; Debiec-Rychter M; Gevaert O; De Raedt T; Van Den Bruel A; de Ravel T; Cichowski K; Kluwe L; Mautner V; Sciot R; Legius E Genes Chromosomes Cancer; 2011 Dec; 50(12):1021-32. PubMed ID: 21987445 [TBL] [Abstract][Full Text] [Related]
40. The role of neurofibromin in N-Ras mediated AP-1 regulation in malignant peripheral nerve sheath tumors. Kraniak JM; Sun D; Mattingly RR; Reiners JJ; Tainsky MA Mol Cell Biochem; 2010 Nov; 344(1-2):267-76. PubMed ID: 20680410 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]